Table 4 Multivariate analysis: Hazards of progression and/or death.

From: Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients

 

PFS (entire cohort)

 

PFS (recent cohort)

 

OS (entire cohort)

 

Variable

Hazards ratio

p-value

Hazards ratio

p-value

Hazards ratio

p-value

R-ISS 1

1

 

1

 

1

 

R-ISS 2

1.86 (1.40–2.46)

<0.001

1.44 (0.80–2.59)

0.220

1.85 (1.31–2.62)

<0.001

R-ISS 3

3.26 (2.18–4.88)

<0.001

2.36 (0.79–7.07)

0.125

3.66 (2.32–5.79)

<0.001

Induction with DRVd

0.28 (0.14–0.56)

<0.001

0.38 (0.18–0.85)

0.017

0.27 (0.08–0.87)

0.028

≤VGPR post-transplant

2.61 (1.75–3.90)

<0.001

2.82 (1.24–6.44)

0.014

1.47 (0.89–2.43)

0.131

No Maintenance

1.51 (1.10–2.07)

0.011

2.91 (1.27–6.67)

0.011

2.12 (1.50–2.99)

<0.001

Back to article page